These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 1098400)

  • 1. Induction of diabetes and oral glucose tolerance tests during and after chronic beta-blockade.
    Vedin A; Wilhelmsson C; Björntorp P
    Acta Med Scand Suppl; 1975; 575():37-40. PubMed ID: 1098400
    [No Abstract]   [Full Text] [Related]  

  • 2. Chronic alprenolol treatment of patients with acute myocardial infarction after discharge from hospital.
    Vedin A; Wilhelmsson C; Werkö L
    Acta Med Scand Suppl; 1975; 575():3-56. PubMed ID: 808105
    [No Abstract]   [Full Text] [Related]  

  • 3. Laboratory analyses during two years' treatment with alprenolol in patients with myocardial infarction.
    Wilhelmsson C; Vedin A
    Acta Med Scand Suppl; 1975; 575():31-5. PubMed ID: 168738
    [No Abstract]   [Full Text] [Related]  

  • 4. Short-term and long-term tolerance to beta-blockade with alprenolol in patients admitted for a suspected acute myocardial infarction.
    Rasmussen SL; Pedersen F
    Acta Med Scand Suppl; 1984; 680():40-9. PubMed ID: 6375280
    [No Abstract]   [Full Text] [Related]  

  • 5. Carbohydrate tolerance status in patients with myocardial infarction.
    Rahman MA; Begum H; Samad A; Shahjehan S
    Z Naturforsch C J Biosci; 1990; 45(1-2):125-8. PubMed ID: 2331285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of beta-blockade on glucose tolerance and insulin release in adult diabetes.
    Holm G; Johansson S; Vedin A; Wilhelmsson C; Smith U
    Acta Med Scand; 1980; 208(3):187-91. PubMed ID: 7001862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of alprenolol in the secondary prevention of myocardial infarction.
    Jürgensen HJ
    Acta Med Scand Suppl; 1984; 680():59-64. PubMed ID: 6375282
    [No Abstract]   [Full Text] [Related]  

  • 8. Reduction of sudden deaths after myocardial infarction by treatment with alprenolol. Preliminary results.
    Wilhelmsson C; Vedin JA; Wilhelmsen L; Tibblin G; Werkö L
    Lancet; 1974 Nov; 2(7890):1157-60. PubMed ID: 4139587
    [No Abstract]   [Full Text] [Related]  

  • 9. [Glycide tolerance and its relationships after myocardial infarct].
    Válek J; Slabochová Z; Hammer J; Stolz I; Kaucká J; Grafnetter D
    Vnitr Lek; 1980 Jun; 26(6):557-62. PubMed ID: 6996312
    [No Abstract]   [Full Text] [Related]  

  • 10. Does hyperglycaemia or hyperinsulinaemia characterise the patient with chemical diabetes?
    Reaven GM; Olefsky J; Farquhar JW
    Lancet; 1972 Jun; 1(7763):1247-9. PubMed ID: 4113513
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of alprenolol on mortality among patients with definite or suspected acute myocardial infarction. Preliminary results.
    Andersen MP; Bechsgaard P; Frederiksen J; Hansen DA; Jürgensen HJ; Nielsen B; Pedersen F; Pedersen-Bjergaard O; Rasmussen SL
    Lancet; 1979 Oct; 2(8148):865-8. PubMed ID: 90964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effect of alprenolol as antihypertensive agent.
    Bengtsson C
    Acta Med Scand Suppl; 1974; 554():9-14. PubMed ID: 4593676
    [No Abstract]   [Full Text] [Related]  

  • 13. QT time in patients treated with alprenolol or placebo after myocardial infarction.
    Nyberg G; Vedin A; Wilhelmsson C
    Br Heart J; 1979 Apr; 41(4):452-5. PubMed ID: 380606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term treatment with beta-blockers after myocardial infarction.
    Ahlmark G; Saetre H
    Eur J Clin Pharmacol; 1976 Jun; 10(2):77-83. PubMed ID: 134897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Reduction of mortality in acute myocardial infarction in patients treated with alprenolol. Preliminary results].
    Andersen M; Bechsgaard P; Frederiksen J; Hansen DA; Jürgensen HJ; Nielsen PB; Pedersen F; Pedersen-Bjergaard O; Rasmussen SL
    Ugeskr Laeger; 1979 Nov; 141(45):3083-6. PubMed ID: 43001
    [No Abstract]   [Full Text] [Related]  

  • 16. Behavior of glycemia and serum insulin level (IRI) in myocardial infarction after oral glucose load.
    Lawecki J; Kuch J; Ceremuzyński L; Rogala H
    Pol Med J; 1972; 11(2):281-90. PubMed ID: 5071515
    [No Abstract]   [Full Text] [Related]  

  • 17. The effects of long-term therapy with oral hypoglycemic agents on the oral glucose tolerance test dynamics in male chemical diabetics.
    Tan MH; Graham CA; Bradley RF; Gleason RE; Soeldner JS
    Diabetes; 1977 Jun; 26(6):561-70. PubMed ID: 324835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Reduction of sudden death after myocardial infarct with chronic alprenolol treatment].
    Tibblin G; Vedin A; Wilhelmsen L; Werkö L; Wilhelmsson C
    Lakartidningen; 1975 Jun; 72(25):2683-6. PubMed ID: 1095869
    [No Abstract]   [Full Text] [Related]  

  • 19. Angina pectoris, hypertension, decompensation and return to work during two years' follow-up.
    Vedin A; Wilhelmson C
    Acta Med Scand Suppl; 1975; 575():25-30. PubMed ID: 1098399
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term tolbutamide treatment after myocardial infarction. A clinical and biochemical study of 178 patients without overt diabetes.
    Paasikivi J
    Acta Med Scand Suppl; 1970; 507():1-82. PubMed ID: 4948308
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.